Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 9 ... is also slightly favorable to the recently reported median survival of 9.2 months1 with Avastin® (bevacizumab) in patients with recurrent high-grade glioma. ...
2009 NOV 9 ... favorable to the recently reported median survival of 9.2 months1 with bevacizumab (Avastin®) in patients with recurrent high-grade glioma. "These are ...
2009 NOV 1 ... on global commercialization of the company's diverse oncology pipeline, including Avastin=AE, Rituxan=AE and Herceptin=AE. Prior to his time at Genentech, Mr. Clark was president ...
2009 NOV 9 ... recurrence. Therefore, sublesional injections of the antiangiogenic agent bevacizumab (Avastin) were given to assess the effect on disease recurrence and phonatory function," ...
2009 OCT 12 ... label, multicenter, randomized Phase II clinical trials with Imprime PGG in combination Avastin® (Bevacizumab) and two chemotherapeutic agents in patients with non-small cell lung ...
2009 OCT 12 ... R&D, in an effort to emulate the success of new targeted therapies such as Herceptin, Avastin, Glivec, Nexavar and Erbitux. Underpinning that success have been real ...
2009 NOV 2 ... conducted a study "To compare outcomes after switching from intravitreal bevacizumab (Avastin) to ranibizumab (Lucentis) in patients with neovascular age-related macular degeneration ...
2009 NOV 23 ... compare the effectiveness of three consecutive intravitreal injections of bevacizumab (Avastin) and ranibizumab (Lucentis) in patients with treatment-naive neovascular age-related ...
2009 NOV 16 ... Roche Holding, Ltd., including the right to receive 60% of the royalties from sales of Avastin=AE (Bevacizumab), Herceptin=AE (Trastuzumab), Lucentis=AE (Ranibizumab) and Xolair=AE ...
2009 NOV 9 ... Roche Holding, Ltd., including the right to receive 60% of the royalties from sales of Avastin=AE (Bevacizumab), Herceptin=AE (Trastuzumab), Lucentis=AE (Ranibizumab) and Xolair=AE ...
2009 NOV 2 ... top selling monoclonal antibody therapeutics such as Rituxan=AE, Herceptin=AE, Avastin=AE and Lucentis=AE. Dr. Garnick will be responsible for overseeing Peregrine's ...
2009 NOV 23 ... Combination chemotherapy is the standard of care in metastatic disease Avastin is used predominantly in the US in the first-line setting Erbitux is ...
2009 OCT 12 ... published their study in Acta Ophthalmologica (Efficacy of intravitreal bevacizumab (Avastin(®)) therapy for early and advanced neovascular age-related macular degeneration. ...
2009 OCT 12 ... "To determine the efficacy of bevacizumab (Avastin), an anti-VEGF monoclonal antibody, administrated via subconjunctival injection as a ...
2009 NOV 23 ... and Wyeth's HKI-272. The report also finds that sales of Roche/Chugai's Avastin for breast cancer will increase by four percent from 2008 to 2018, largely owing to ...
2009 OCT 12 ... evaluate the short- and long-term in vivo safety and efficacy of topical bevacizumab (Avastin) application for treatment of corneal neovascularization secondary to a variety of ...
2009 OCT 12 ... and FLIRI (5-FU + leucovorin + irinotecan)], two biologically targeted drugs (avastin and erbitux), and two hydroxamic acid derivatives (vorinostat, SAHA ®, and a novel ...
2009 OCT 12 ... of tumors with a one-time i.v. injection of GLV-1h68 and multiple i.p. injections of Avastin," wrote A. Frentzen and colleagues. The researchers concluded: "Taken ...
